Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has been assigned a consensus rating of “Buy” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $42.71.

PRTK has been the subject of a number of recent analyst reports. BidaskClub upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. Raymond James Financial, Inc. reiterated a “strong-buy” rating and issued a $36.00 price target on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. Zacks Investment Research lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Paratek Pharmaceuticals in a research report on Tuesday, August 8th. Finally, ValuEngine lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th.

TRADEMARK VIOLATION WARNING: “Paratek Pharmaceuticals, Inc. (PRTK) Given Average Recommendation of “Buy” by Brokerages” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/19/paratek-pharmaceuticals-inc-prtk-given-average-recommendation-of-buy-by-brokerages.html.

A number of institutional investors have recently made changes to their positions in PRTK. Bank of New York Mellon Corp lifted its stake in Paratek Pharmaceuticals by 17.5% in the 1st quarter. Bank of New York Mellon Corp now owns 84,045 shares of the specialty pharmaceutical company’s stock worth $1,618,000 after acquiring an additional 12,505 shares in the last quarter. American International Group Inc. lifted its stake in Paratek Pharmaceuticals by 34.1% in the 1st quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock worth $214,000 after acquiring an additional 2,824 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in Paratek Pharmaceuticals by 11.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 75,076 shares of the specialty pharmaceutical company’s stock worth $1,445,000 after acquiring an additional 7,844 shares in the last quarter. Vanguard Group Inc. lifted its stake in Paratek Pharmaceuticals by 9.5% in the 1st quarter. Vanguard Group Inc. now owns 724,300 shares of the specialty pharmaceutical company’s stock worth $13,942,000 after acquiring an additional 63,121 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Paratek Pharmaceuticals by 10.7% in the 1st quarter. Geode Capital Management LLC now owns 148,962 shares of the specialty pharmaceutical company’s stock worth $2,867,000 after acquiring an additional 14,392 shares in the last quarter. 82.46% of the stock is owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals (PRTK) opened at $20.40 on Friday. Paratek Pharmaceuticals has a 52 week low of $12.55 and a 52 week high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.